Telavancin May Require Informed Consent For Women Of Childbearing Age
This article was originally published in The Pink Sheet Daily
Executive Summary
The Anti-Infective Drugs Advisory Committee will consider whether a REMS is necessary given the teratogenic risks of Theravance’s antibiotic.
You may also be interested in...
FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.
FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.
Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee
FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.